Rehabilitation for nerve damage caused by chemotherapy
Sensory Rehabilitation in Chemotherapy Induced Peripheral Neuropathy (CIPN)
This study is testing new rehabilitation techniques to help people with nerve damage from chemotherapy feel better and improve their sensory function.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 12 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | Assaf-Harofeh Medical Center Government |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Beer Yaaqov) |
| Trial ID | NCT05382520 on ClinicalTrials.gov |
What this trial studies
This study focuses on sensory rehabilitation techniques for patients suffering from chemotherapy-induced peripheral neuropathy (CIPN). It involves the use of questionnaires and physiotherapy practices to assess and improve sensory function in affected individuals. The approach aims to retrain the sensory pathways that may have been disrupted due to chemotherapy. Participants will be evaluated based on their reported symptoms and treatment outcomes over time.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and over who have experienced CIPN for more than three months following chemotherapy.
Not a fit: Patients with pre-existing neuropathy or significant orthopedic impairments may not benefit from this study.
Why it matters
Potential benefit: If successful, this could significantly improve the quality of life for patients suffering from CIPN by alleviating neuropathic pain and enhancing sensory function.
How similar studies have performed: While there is ongoing research in sensory rehabilitation for neuropathies, this specific approach to CIPN is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 18 and over who suffer from chemotherapy-induced neuropathy (CIPN), according to the patient's report, more than 3 months since the end of the chemotherapy treatment. Exclusion Criteria: 1. Sensory damage / neuropathy that existed even before the start of chemotherapy 2. Incidents of recurrent falls even before the start of chemotherapy (over 2 falls for 6 months) 3. Central nervous system involvement 4. Major pre-morbid orthopedic lower limb impairment 5. Hebrew language not sufficient for assessment and treatment
Where this trial is running
Beer Yaaqov
- Shamir medical center — Beer Yaaqov, Israel (Recruiting)
Study contacts
- Principal investigator: Rotem Merose, Dr. — Assaf Harofee MC
- Study coordinator: Hadas Ofek
- Email: hadasbarkolofek@gmail.com
- Phone: 972544666412
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.